| rivaroxaban / Generic mfg. |
| Recruiting | 2 | 600 | | | South East Sydney and Illawarra Area Health Service , Thrombosis and Haemostasis Society of Australia and New Zealand | Cancer-associated thrombosis, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism | | | | |
4445a: A Phase 2 study evaluating andexanet alfa and XARELTO® (rivaroxaban) |
|
|
| Ongoing | 2 | 0 | RoW | andexanet alfa (PRT4445) | Portola | Healthy volunteers | | | | |
|
|
| Ongoing | 2 | 81 | Europe | Rivaroxaban 20mg, N/A, Film-coated tablet | Manchester University NHS Foundation Trust, NIHR Clinical Scientist Award | Breast Cancer, Breast Cancer, Diseases [C] - Cancer [C04] | | | | |
2012-002345-38: Comparison of rivaroxaban (Xarelto®; Bayer HealthCare), fixed-dose oral anticoagulant (blood thinner), versus warfarin in patients with antiphospholipid syndrome (called APS), with or without \'lupus\' (systemic lupus erythematosus) |
|
|
| Ongoing | 2 | 156 | Europe | Rivaroxaban, Warfarin, Xarelto, The generic name is warfarin and many producers will be involved, Xarelto, The generic name is warfarin and many producers will be involved | University College London, Arthritis Research UK, Bayer plc | Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE). | | | | |
2016-003240-37: Study to evaluate the effect of rivaroxaban in patients with advanced liver disease with portal vein thrombosis Estudio para evaluar el efecto del rivaroxaban en pacientes con enfermedad hepática en fase avanzada con trombosis portal |
|
|
| Ongoing | 2 | 134 | Europe | Film-coated tablet, Xarelto® | Fundación para la Investigación Biomédica Hospital Ramón y Cajal, Carlos III Health Institute (National Health System) | Liver cirrhosis and portal vein thrombosis Cirrosis hepática y trombosis de la vena porta, Liver disease in advanced stage, with the possibility of developing portal vein thrombosis (occlusion of the vein that carries blood to the liver) Enfermedad hepática en fase avanzada, con posibilidad de desarrollar trombosis en la vena porta (oclusión de la vena que lleva la sangre al hÃgado), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-001567-20: Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study Evaluation de la double antiagrégation plaquettaire versus Rivaroxaban dans les suites de la fermeture d'auricule pour les patients souffrant de fibrillation atriale : Etude randomisée ADRIFT |
|
|
| Not yet recruiting | 2 | 90 | Europe | Xarelto 10mg, Xarelto 15 mg, Kardegic, Plavix 75 mg, Tablet, Powder for oral solution, Xarelto 10mg, Xarelto 15 mg, Kardegic, Plavix 75 mg | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | patients souffrant de fibrillation atriale non valvulaire et ayant subi une fermeture d'auricule gauche, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-001723-12: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome (long-term condition associated with redness, swelling, leg pain, and ulcers as a results of deep vein thrombosis) |
|
|
| Not yet recruiting | 2 | 316 | Europe | Aspirin protect 100 mg, Film-coated tablet, Aspirin protect 100 mg | Universitätsspital Zürich, Klinik für Angiologie, Universitätsspital Zürich, Klinik für Angiologie, Bayer (Schweiz) AG, BARD Medica S.A. | Post-thrombotic syndrome, Post-thrombotic syndrome is a long-term complication of a deep vein thrombosis. It may include following symptoms: pain, swelling, itching , red/brown skin discoloration and ulcer at the affected leg., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-004507-13: A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate. |
|
|
| Not yet recruiting | 2 | 1200 | Europe, RoW | Abelacimab, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets, MAA868, Concentrate for solution for injection, Film-coated tablet, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets | Anthos Therapeutics, Anthos Therapeutics | Atrial Fibrillation, A heart condition that causes an irregular and abnormally fast heart rate., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000031649: A prospective, randomized, controlled study of rivaroxaban in the prevention of venous thrombosis in patients with deep vein catheterization chemotherapy for breast cancer |
|
|
| Completed | 2 | 200 | | rivaroxaban 10mg.po.qd ;Without preventive anticoagulant | Beijing Chaoyang District San Huan Cancer Hospital; Beijing Chaoyang District San Huan Cancer Hospital, Apply for funds from chaoyang district science and technology commission | Venous thrombosis of breast cancer | | | | |
2020-002282-33: Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT) |
|
|
| Not yet recruiting | 2 | 400 | Europe | Xarelto, Film-coated tablet, Solution for injection, Solution for injection in pre-filled syringe, Xarelto | Charité - Universitaetsmedizin Berlin, Bayer AG, DZHK - Deutsches Zentrum für Herz-Kreislauf-Forschung | Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury, Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury, Diseases [C] - Virus Diseases [C02] | | | | |
2021-005788-34: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect Plaatjesremming versus directe antistollingsmedicatie bij patiënten die sluiting van een patent foramen ovale of atriaal septum defect ondergaan |
|
|
| Ongoing | 2 | 52 | Europe | Tablet, Plavix, Acetylsalicylylzuur Cardio (and others), Xarelto | St. Antonius Hospital, St. Antonius Onderzoeksfonds | Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. Atriaal septum defect of patent foramen ovale met een indicatie om percutaan te sluiten met een implantaat, Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. Atriaal septum defect of patent foramen ovale met een indicatie om via de lies (percutaan) te sluiten met een implantaat, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ECRU, NCT05088928: Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care |
|
|
| Not yet recruiting | 2 | 40 | RoW | Apixaban, ECRU Tablets, Rivaroxaban, Rivascot tablets | Scotmann Pharmaceuticals, Rawalpindi Medical College | COVID-19 | 05/22 | 08/22 | | |
NCT05006287: The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery |
|
|
| Active, not recruiting | 2 | 100 | Canada | Non-vitamin K oral anticoagulants (NOACs), Apixaban, Dabigatran, Edoxaban, Rivaroxaban, Warfarin | St. Paul's Hospital, Canada | Atrial Fibrillation | 05/24 | 05/24 | | |
| Withdrawn | 2 | 206 | NA | Warfarin, Coumadin, Dabigatran, Pradaxa, Rivaroxaban, Xarelto, Apixaban, Eliquis, Edoxaban, Lixiana | Laval University | Anticoagulant-induced Bleeding | 01/23 | 03/23 | | |
| Recruiting | 2 | 60 | RoW | Rivaroxaban 15 MG, Clopidogrel 75mg, Acetylsalicylic acid 100mg, Aspirin, Clopidogrel 75 Mg Oral Tablet, Plavix | Instituto Nacional de Cardiologia Ignacio Chavez | Acute Coronary Syndrome, Coronary Artery Ectasia | 06/23 | 07/24 | | |
ARIVA, NCT04128956: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS |
|
|
| Terminated | 2 | 172 | Europe | Aspirin 100mg, Aspirin | University of Zurich, University Hospital Heidelberg, Medical University of Vienna, RWTH Aachen University, Klinikum Arnsberg, University Hospital Freiburg | Venous Thromboses, Stent Stenosis | 02/24 | 02/24 | | |
| Active, not recruiting | 2 | 1200 | Europe, Canada, US, RoW | Abelacimab, MAA868, Rivaroxaban | Anthos Therapeutics, Inc., The TIMI Study Group, Fortrea | Atrial Fibrillation (AF), Stroke | 12/23 | 12/25 | | |
|
NCT04593784: Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults |
|
|
| Recruiting | 2 | 108 | US | Ciraparantag, PER977, AMAG 977, Placebo, PBO, Point-of-Care Coagulometer (investigational device), Coagulometer | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Healthy | 12/23 | 12/23 | | |
| Completed | 2 | 272 | Europe | Rivaroxaban 10 MG Oral Tablet [Xarelto] | Insel Gruppe AG, University Hospital Bern, Bayer, Janssen Pharmaceuticals | Bariatric Surgery | 12/23 | 12/23 | | |
NCT06220123: A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery |
|
|
| Not yet recruiting | 2 | 350 | NA | SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets | Beijing Suncadia Pharmaceuticals Co., Ltd | Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | 06/25 | 07/25 | | |
| Active, not recruiting | 2 | 43 | Europe | Rivaroxaban, Warfarin | University College, London, University College London Hospitals, Barking, Havering and Redbridge University Hospitals NHS Trust, Hammersmith Hospitals NHS Trust, Epsom and St Helier University Hospitals NHS Trust, Barts & The London NHS Trust, King's College Hospital NHS Trust, Versus Arthritis (Funder) | Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke, Brain Ischemia | 02/25 | 08/25 | | |
